Results 101 to 110 of about 105,256 (293)

Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? [PDF]

Can J Gastroenterol Hepatol, 2022
Wetten A, Ogle L, Mells G, Hegade VS, Jopson L, Corrigan M, Palmer J, Johansson M, Bäckström T, Doverskog M, Jones DEJ, Dyson JK.   +11 more
europepmc   +1 more source

The Relationship Between Aldose Reductase and Isoxazole Derivatives: An In Vitro and In Silico Approach to Its Correlation With Diabetic Conditions

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Diabetes mellitus (DM), which can result in a number of problems such as cataracts, neuropathy, retinopathy, nephropathy, and several cardiovascular illnesses, continues to be a growing issue despite major advancements in treatment approaches.
Ahmet Esat Göner, Hatice Esra Duran
wiley   +1 more source

Dual Molecules Targeting 5-HT₆ and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation. [PDF]

ACS Chem Neurosci, 2023
Marcinkowska M, Mordyl B, Siwek A, Głuch-Lutwin M, Karcz T, Gawalska A, Sapa M, Bucki A, Szafrańska K, Pomierny B, Pytka K, Kotańska M, Mika K, Kolaczkowski M.   +13 more
europepmc   +1 more source

Cloning and functional expression of GABA_B receptors from Drosophila [PDF]

, 2001
Mario Mezler, Thomas Müller, K. Raming
openalex   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

PCDH19 interplay with GABA(A) receptors: a window to DEE9 pathogenetic mechanisms. [PDF]

Neural Regen Res, 2022
Mazzoleni S, Bassani S.
europepmc   +1 more source

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Correction to: Recruitment of Plasma Membrane GABA-A Receptors by Submembranous Gephyrin/Collybistin Clusters. [PDF]

Cell Mol Neurobiol, 2022
George S, Chiou TT, Kanamalla K, De Blas AL.   +3 more
europepmc   +1 more source

Rubrolides A, D, P, T, U: Total Syntheses and Antibacterial Evaluation of Highly Brominated Marine Natural Products

ChemistryEurope, EarlyView.
Following the Danube Flow. The first total syntheses of highly brominated rubrolides T, U, and U‐analog, together with the efficient and divergent syntheses of rubrolides A, D, and P. The dibrominated key intermediate, obtained via a Suzuki‐Miyaura cross‐coupling reaction, is the centerpiece of the synthesis.
Jasmin Janneschütz, Paul G. Schebek, Alexander Meyer, Celina Haller, Sophia Khom, Wolfgang R. Streit, Ifey Alio, Nina Schützenmeister   +7 more
wiley   +1 more source

Xenopus Oocytes: A Tool to Decipher Molecular Specificity of Insecticides towards Mammalian and Insect GABA-A Receptors. [PDF]

Membranes (Basel), 2022
Bertaud A, Cens T, Mary R, Rousset M, Arel E, Thibaud JB, Vignes M, Ménard C, Dutertre S, Collet C, Charnet P.   +10 more
europepmc   +1 more source